Back

Effect Of Pneumococcal Conjugate Vaccine On The Length Of Hospitalization In Children Under Five With Pneumonia In Burkina Faso

Bountogo, M.; Sanogo, B.; Da, M.; Tall, H.; Martin, C.; Ouedraogo, W. A.; Ouedraogo, A.-S.; Betsem, E.; Meda, N.

2025-11-19 infectious diseases
10.1101/2025.11.17.25340457 medRxiv
Show abstract

BackgroundPneumococcus is a leading cause of childhood morbidity and mortality worldwide. We assessed the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on the hospitalization length among children under five years hospitalized for pneumonia in Burkina Faso. MethodsWe conducted a secondary analysis of data collected from hospitalized pneumonia cases participating in a diagnostic validation study between December 2015 and January 2017. A Cox proportional hazards model was used to assess the association between vaccination status and time to discharge. ResultsA total of 280 children were included, of whom 187 (66.8%) had received three PCV13 doses. The mean hospitalization duration was 7.99 days (95% CI 7.17-8.81) for those fully vaccinated vs. 10.44 days (95% CI 9.07-11.80) among children with <3 doses. Full vaccination was associated with a significantly higher recovery rate (aHR: 1.45; 95% CI: 1.11-2.08, p = 0.01). ConclusionPCV13 significantly reduces hospitalization length due to pneumonia among children under five in Burkina Faso.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.